YPC-22026 manufacturers
- YPC-22026
-
- $176.00
-
2026-07-25
- CAS:1964457-41-7
- Purity: 99.98%
- Supply Ability: 10g
|
| | YPC-22026 Basic information |
| Product Name: | YPC-22026 | | Synonyms: | YPC-22026;Pyridine, 3-[2-[5-[2-(trifluoromethoxy)phenyl]-1,3,4-oxadiazol-2-yl]ethynyl]- | | CAS: | 1964457-41-7 | | MF: | C16H8F3N3O2 | | MW: | 331.25 | | EINECS: | | | Product Categories: | | | Mol File: | 1964457-41-7.mol |  |
| | YPC-22026 Chemical Properties |
| Boiling point | 438.5±55.0 °C(Predicted) | | density | 1.47±0.1 g/cm3(Predicted) | | pka | 3.28±0.12(Predicted) |
| | YPC-22026 Usage And Synthesis |
| Description | YPC-22026 is a novel inducer of tumor regression accompanied by the suppression of ZNF143-regulated genes in a mouse xenograft model. | | Uses | YPC-22026 is a zinc-finger protein 143 (ZNF143) inhibitor with an IC50 value of 9.0 μM. YPC-22026 is a potent tumor regression inducer. YPC-22026 exhibits anti‐tumor activities[1]. | | in vivo | YPC‐22026 (50-100 mg/kg; i.p; on days 1, 2, 3, 8, 9, 12, and 16) significantly inhibits the growth of tumors in the HCT116 xenograft model[1].
In the PC‐3 xenograft model, YPC‐22026 (75 mg/kg; ip) significantly decreases in the intratumoral expression levels of all ZNF143 target genes, RAD51, PLK1, and Survivin[1]. | Animal Model: | Six‐week‐old male BALB/c nude mice injected with HCT116 cells[1] | | Dosage: | 50 mg/kg and 100 mg/kg | | Administration: | i.p; on days 1, 2, 3, 8, 9, 12, and 16 (50 mg/kg ); on days 1, 2, 3, 12, and 16 (100 mg/kg) | | Result: | Significantly inhibited the growth of tumors. |
| | References | [1] Hirotaka Haibara, et al. YPC-21661 and YPC-22026, novel small molecules, inhibit ZNF143 activity in vitro and in vivo. Cancer Sci. 2017 May;108(5):1042-1048. DOI:10.1111/cas.13199 |
| | YPC-22026 Preparation Products And Raw materials |
|